CCHT(SZ:000661)2022-12-07 08:24Group 1: Company Control and Management - The change of the actual controller to Changchun Longxiang Group will not impact the company's development strategy or daily operations [3] - The local state-owned enterprise reform implementation measures have not yet been released, awaiting guidance from relevant authorities [3] - The increase in stock holdings by directors, supervisors, and executives is a voluntary action based on confidence in the company's future, not a regulatory requirement [4] Group 2: Market and Product Development - The market sales of long-acting growth hormone are progressing as planned, with sales performance meeting expectations [6] - The production of follicle-stimulating hormone is being organized, with sales expected to commence as products are sold through public hospital tenders [6] - The clinical trial for the nasal spray flu vaccine is expected to take about one year, with the launch date dependent on regulatory review [7] Group 3: Investment and Partnerships - The establishment of Shanghai Tongxin Hospital Management Co., Ltd. is underway, with registration and acquisition research progressing as planned [5] - The project for the heart stent by Xi'an Aide Wansi is currently in preclinical research, showing optimistic progress [7] - The self-inspection report for the Aisena peptide project has been submitted, currently awaiting review by the regulatory department [7]